An interventional study of D-dimer-guided adjustment stratege and Thepeautic-heparin therapy in Extracorporeal Membrane Oxygenation Complication, Thrombosis and Hemorrhage, sponsored by Wuhan Asia Heart Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Wuhan Asia Heart Hospital · Not applicable, Interventional, and Treatment
This was a prospective, cohort study.
Adult Patients receiving ECMO surpport in Wuhan Asia Heart Hospital were enrolled by cohort. Unfractionated heparin was used for Anticoagulation therapy, APTT or Anti-Xa activity is monitored for dose adjustment. Meanwhile, D-dimer is mornitored. If D-dimer levels continue to rise (>1.5 times previous result ), increase the dose of heparin to reach the upper limit of the treatment target; If the D-dimer levels is stable (\<1.5 times previous result ) or is decreasing, the anticoagulation dose is maintained at current level (no active bleeding) or decreased (active bleeding). All patients were followed up The occurrence of endpoints during in-hospital and 30 days after discharge, including bleeding events, thrombotic events and all-cause deaths were recorded.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
This study's planned enrollment of 300 is above the median of 83 across 530 interventional studies indexed under Thrombosis.
Browse Thrombosis studies →Wuhan Asia Heart Hospital is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
D-dimer and anti-Xa are mornitored. If D-dimer levels continue to rise (\>1.5 times previous result ), increase the dose of heparin to reach the upper limit of the treatment target; If the D-dimer levels is stable (\<1.5 times previous result ) or is decreasing, the anticoagulation dose is maintained at current level (no active bleeding) or decreased (active bleeding).
Diagnostic Test: D-dimer-guided adjustment stratege
Heparin dose adjusted according to anti-Xa activity or activated partial thromboplastin time (aPTT). The target range is aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels (0.3 U/ml to 0.7 U/ml) for unfractionated heparin.
Diagnostic Test: Thepeautic-heparin therapy
D-dimer-guided adjustment stratege
Also known as: Heparin
0.3-0.7U/ml of anti-Xa activity or APTT 1.5-2.5 times of control
Thrombotic events
Stroke, DVT, PE, Peripheral arterial embolism, ACS etc.
Time frame: 24 months
hemorrhagic events
cerebral hemorrhage,Gastrointestinal bleeding etc.
Time frame: 24 months
all-cause deaths
all-cause deaths
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2019 (actual). Primary completion is estimated for Dec 2023, 57 months after the start.
Of 108 non-industry interventional studies with no phase under Thrombosis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 57 months is above that.
Counting every sponsor, half of 115 studies reached it within 24 months; a quarter within 9 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wuhan Asia Heart Hospital